Differences and Similarities Between the EULAR/ASAS-EULAR and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706
Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356
Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.
After JAK Inhibitor Failure: To Cycle Or To Switch, That Is The Question – Data From The JAK-Pot Collaboration of Registries
Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222835
Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Blocking the IL-6R is a major therapeutic advance for many diseases in adults and children. Updated consensus statement provides guidance to rheumatologists and other experts, as well as patients and administrators, on managing patients with the use of drugs blocking the IL-6 pathway.
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586
Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.